Pfizer Inc. (NYSE:PFE) recently purchased the biggest share percentage in AM-Pharma that is currently developing drugs for conditions such as Kidney injury.
AM-Pharma is a promising Dutch Pharmaceutical company. The fact that Pfizer decided to buy some stake in the company meaning they have a lot of faith on the products from AM-Pharma. Pfizer spent $87.5 million in the venture and will probably pay more in upwards of about $512 million depending on the options available as well as the product quality.
There is a chance that more options will be available once the drug manufacturer enters the second trial period. Phase II trials will be focused on serious kidney injury associated with sepsis. The results from the phase II drug trials are expected to be out by the end of 2016.
In March 2014, AM-Pharma reported a successful phase I data for a drug called recap. The name of the drug was derived as an acronym from its description as a recombinant human Alkaline Phosphatase.
According to Pfizer, the research data reveals the drug’s ability to tackle kidney injuries occurring in line with the manifestation of Sepsis. According the firm, there is no medicine currently sanctioned for the medical condition. The only options available are supportive care and dialysis. The company might possibly kill two birds with one stone if the drug proves viable for the treatment of ulcerative colitis.
At one point in history, Pfizer was ranked at the top of the food chain as one of the most successful medicinal drug manufacturer. The company’s success was pegged on drugs such as Lipitor which acted against cholesterol. However over time, the company’s patents for such drugs failed to hold and thus new and better drugs to enter the market.
Pfizer Inc. (NYSE:PFE) and its other competitors have been on constant battles to improve their portfolio and sell a wider variety of other drugs. The unfortunate thing is the fact that the competition has led to constant price depreciations, leaving the firms to scramble over low profits.
